Waxman reiterates scientific review request

Share this article:
Incoming Committee on Government Reform Chair Rep. Henry Waxman (D-CA) reiterated his request that the FDA conduct a thorough scientific review of phenylephrine's effectiveness at 10 mg as used in reformulated OTC decongestants, citing a DTC ad for Schering-Plough's Claritin-D indicating the company will not reformulate it.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions